Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Shares Outstanding (Weighted Average) (2016 - 2025)

PAVmed has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $670466.0 for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 107.96% year-over-year to $670466.0; the TTM value through Dec 2025 reached $670466.0, up 107.96%, while the annual FY2025 figure was $670466.0, 107.96% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $670466.0 at PAVmed, down from $21.6 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $89.8 million in Q3 2022 and troughed at $322407.0 in Q4 2024.
  • A 5-year average of $35.6 million and a median of $13.9 million in 2025 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 95.54% in 2024 and later skyrocketed 107.96% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $77.5 million in 2021, then plummeted by 92.34% to $5.9 million in 2022, then increased by 21.78% to $7.2 million in 2023, then crashed by 95.54% to $322407.0 in 2024, then skyrocketed by 107.96% to $670466.0 in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PAVM at $670466.0 in Q4 2025, $21.6 million in Q3 2025, and $16.0 million in Q2 2025.